• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CMAJ . The mobility gap: estimating mobility thresholds required to control SARS-CoV-2 in Canada

tetano

Editor, Senior Moderator
CMAJ


. 2021 Apr 7;cmaj.210132.
doi: 10.1503/cmaj.210132. Online ahead of print.
The mobility gap: estimating mobility thresholds required to control SARS-CoV-2 in Canada


Kevin A Brown[SUP] 1 [/SUP], Jean-Paul R Soucy[SUP] 1 [/SUP], Sarah A Buchan[SUP] 1 [/SUP], Shelby L Sturrock[SUP] 1 [/SUP], Isha Berry[SUP] 1 [/SUP], Nathan M Stall[SUP] 1 [/SUP], Peter J?ni[SUP] 1 [/SUP], Amir Ghasemi[SUP] 1 [/SUP], Nicholas Gibb[SUP] 1 [/SUP], Derek R MacFadden[SUP] 1 [/SUP], Nick Daneman[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Nonpharmaceutical interventions remain the primary means of controlling severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) until vaccination coverage is sufficient to achieve herd immunity. We used anonymized smartphone mobility measures to quantify the mobility level needed to control SARS-CoV-2 (i.e., mobility threshold), and the difference relative to the observed mobility level (i.e., mobility gap).
Methods: We conducted a time-series study of the weekly incidence of SARSCoV-2 in Canada from Mar. 15, 2020, to Mar. 6, 2021. The outcome was weekly growth rate, defined as the ratio of cases in a given week versus the previous week. We evaluated the effects of average time spent outside the home in the previous 3 weeks using a log-normal regression model, accounting for province, week and mean temperature. We calculated the SARS-CoV-2 mobility threshold and gap.
Results: Across the 51-week study period, a total of 888 751 people were infected with SARS-CoV-2. Each 10% increase in the mobility gap was associated with a 25% increase in the SARS-COV-2 weekly case growth rate (ratio 1.25, 95% confidence interval 1.20-1.29). Compared to the prepandemic baseline mobility of 100%, the mobility threshold was highest in the summer (69%; interquartile range [IQR] 67%-70%), and dropped to 54% in winter 2021 (IQR 52%-55%); a mobility gap was present in Canada from July 2020 until the last week of December 2020.
Interpretation: Mobility strongly and consistently predicts weekly case growth, and low levels of mobility are needed to control SARS-CoV-2 through spring 2021. Mobility measures from anonymized smartphone data can be used to guide provincial and regional loosening and tightening of physical distancing measures.
 
Back
Top Bottom